About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

36.51 -1.49 (-3.92%)
Streaming Delayed Price Updated: 3:38 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 80,049
Open 37.25
Bid (Size) 36.26 (400)
Ask (Size) 36.76 (200)
Prev. Close 38.00
Today's Range 36.24 - 38.32
52wk Range 7.255 - 45.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
From Sionna Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-6.9%
-6.9%
1 Month
-15.9%
-15.9%
3 Month
-16.2%
-16.2%
6 Month
+42.0%
+42.0%
1 Year
+135.2%
+135.2%

More News

Read More
News headline image
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar ↗
Via Stocktwits
News headline image
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
News headline image
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial ↗
Via Benzinga
News headline image
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports First Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Sionna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sionna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sionna Therapeutics, Inc. - Common Stock trade on?
Sionna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sionna Therapeutics, Inc. - Common Stock?
The ticker symbol for Sionna Therapeutics, Inc. - Common Stock is SION on the Nasdaq Stock Market
What is the current price of Sionna Therapeutics, Inc. - Common Stock?
The current price of Sionna Therapeutics, Inc. - Common Stock is 36.51
When was Sionna Therapeutics, Inc. - Common Stock last traded?
The last trade of Sionna Therapeutics, Inc. - Common Stock was at 02/27/26 03:38 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.